Here, it is worth noting the remarkable convergence between BIN1 and Tau: (i) BIN1 modulates Tau toxicity in Drosophila and in mouse models [88, 89]; (ii) BIN1 interacts directly with Tau in a phosphorylation-dependent manner [90]; (iii) BIN1 AD risk variants are associated with increased neurofibrillary tangles and higher Braak stages [88, 91, 92]; and (iv) BIN1 AD risk variants are associated with levels of Tau/p-Tau (but not of Ab1-42) in cerebrospinal fluid (CSF) [93] and Tau-PET results (but not amyloid-PET results) in the brain [94, 95]. The gene discussed is MAPT; the disease is amyloidosis.